Mirum Pharmaceuticals Inc. (MIRM)
Mirum Pharmaceuticals: Q2 Results Continue To Show Positive Momentum
Mirum Pharmaceuticals continues to outperform, beating revenue and earnings expectations for two consecutive quarters and raising guidance. Livmarli, Mirum's flagship drug, is driving strong revenue growth, with approvals in both the U.S. and Europe to treat symptoms of rare liver diseases. The analyst community remains unanimously bullish on the stock, and more than a half dozen analyst firms raised their price targets following Q2 results.
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2025 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Christopher Peetz - CEO & Director Eric H. Bjerkholt - Chief Financial Officer Joanne M.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.52 per share a year ago.
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
MIRM jumps 35% in 3 months, driven by soaring Livmarli sales and rising demand for its bile acid products.
Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised
MIRM reports better-than-expected first-quarter 2025 results. The company raises its 2025 revenue guidance.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.54 per share a year ago.
Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call
Mirum Pharmaceuticals, Inc. stock has risen nearly 25% since my "Sell" rating in October, prompting a re-evaluation of the company's performance and prospects. Mirum markets three drugs: LIVMARLI, Cholbam, and Chenodal, with LIVMARLI showing significant growth in treating cholestatic pruritus in ALGS and PFIC. Mirum's 2024 net product sales reached $336.4m, an 88% year-on-year increase, driven by LIVMARLI and the newly acquired bile acid medicines.
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe
MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.
MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates
Mirum's fourth-quarter 2024 earnings miss estimates while revenues beat the same.
